Lung cancer breakthrough: could observation replace surgery?
NCT ID NCT06743555
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surgery. The goal is to see if careful monitoring can be an alternative to surgery without harming outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLETE RESPONSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 3E4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?